Stratigos, A., Sekulic, A., Peris, K., Bechter, O., Kaatz, M., Lewis, K., Basset-Segiun, N., Chang, A. L., Dalle, S., Orland, A. F., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M., Dummer, R., Li, S., Mohan, K., Coates, E., Jankovic, V., Flaschi, N., Okoye, E., Bassukas, I., Loquai, C., De Giorgi, V., Eroglu, Z., Gutzmer, R., Ulrich, J., Puig, S., Seebach, F., Thurston, G., Lowy, I., Bowler, T. and Fury, M. (2021) “Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs)”, SKIN The Journal of Cutaneous Medicine, 5(1), p. s4. doi: 10.25251/skin.5.supp.4.